IOL Chemicals and Pharmaceuticals Limited share price

IOL Chemicals and Pharmaceuticals Limited manufactures and sells pharmaceutical and chemical products in India and internationally. It operates through two segments: Pharmaceuticals and Specialty Chemicals. The Chemical segment offers ethyl acetate, iso butyl benzene, acetyl chloride, mono chloro acetic acid, and acetic anhydride to the food processing, flexible packaging, pharmaceuticals, textiles, ink, paint, plasticizers and ploymers, and chemical intermediates industries. The Pharmaceutical segment provides active pharmaceutical ingredients, such as ibuprofen, metformin, fenofibrate, lamotrigine, clopidogrel bisulphate, pantoprazole sodium, ursodeoxycholic acid, losartan potassium, gaba…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: IOLCPISIN INE485C01029

16 Oct 2026, 3:29 PM IST₹194.69▼ 0.39 (0.20%)

Market Cap₹ 5,715 Cr.
Current Price₹ 194.69
High / Low₹ 224 / 67
Stock P/E34.0
Book Value₹ 61
Dividend Yield0.51 %
ROCE10.2 %
ROE7.90 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 5.72
Price / Book3.18
OPM8.2 %
Debt / Equity0.08
Sales growth (3Y)1.5 %
Profit growth (3Y)-0.4 %
Promoter holding62.3 %
EV / EBITDA18.1
Beta0.54
All-time high₹ 224

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
IOLCP	+0.06%	+18.66%	+127.52%	+136.68%	+98.56%	+28.33%	+9.92%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

IOL Chemicals and Pharmaceuticals Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹5,715 crore.
It trades at 34.0 times its last 12 months' earnings and 3.2 times book value.
Revenue grew 1.5% a year over the last 3 years, profit -0.4% a year.
Return on equity was 7.9% and return on capital employed 10.2% in the latest year.
Debt was 0.08 times shareholders' equity.
The share price is 13.1% below its 52-week high and up 98.6% over one year.
Promoters and insiders hold about 62.3%; institutions about 1.8%.

Pros

Company is almost debt-free (debt is 0.08 times equity).
Latest quarter (Jun 2026): sales up 37% and profit up 90% from a year ago.
Promoters have raised their holding by 14.09 points over 3 years, to 62.28%.
Institutional (FII + DII) holding has risen by 5.0 points over 3 years.
Promoters hold a large stake of 62.28%.

Cons

Return on equity has been low: 7.5% on average over the last 3 years.
Sales growth has been slow: 1.5% a year over the last 3 years.
Profit growth has been weak: -0.4% a year over the last 3 years.
Trades at 34.0 times earnings, above its 3-year median of 21.1.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About IOL Chemicals and Pharmaceuticals Limited

Employees: 3,095
Head office: Ludhiana

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	IOL Chemicals and Pharmaceuticals	194.69	34.0	5,715	0.51	64	89.80	756	37.08	10.2	7.9	3.18	8.2	0.08	62.28	2,319	1.5
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 40 Co.	1,712.85	31.0	23,878	0.37	679	24.47	5,999	21.59	14.6	16.5	4.69	17.0	0.21	55.20	20,499	13.5

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	563	545	520	504	502	526	523	528	552	568	580	619	756
YOY Sales Growth %	-0.32%	0.72%	-0.59%	-14.18%	-10.80%	-3.59%	0.56%	4.73%	9.82%	7.95%	10.91%	17.37%	37.08%
	491	481	476	454	451	484	476	465	490	510	523	527	653
Material Cost %	65%	65%	68%	64%	67%	68%	68%	66%	66%	65%	66%	60%	63%
Employee Cost %	10%	9%	9%	10%	11%	11%	10%	10%	10%	11%	10%	11%	9%
Other Expenses %	13%	14%	14%	16%	12%	13%	13%	13%	12%	14%	14%	14%	14%
Operating Profit	73	64	44	50	51	42	47	63	62	57	57	92	103
OPM %	13%	12%	9%	10%	10%	8%	9%	12%	11%	10%	10%	15%	14%
	7	7	8	8	7	6	4	5	7	7	5	2	8
Exceptional items											-11
Interest	4	4	4	3	2	4	4	4	4	3	4	3	4
Depreciation	14	16	16	16	17	18	19	19	20	20	20	20	21
Profit before tax	61	51	32	37	40	26	28	45	46	40	28	71	87
	25%	26%	28%	26%	24%	26%	26%	30%	25%	26%	25%	25%	26%
Current tax	15	11	6	5	9	5	4	7	10	9	6	15	22
Deferred tax	1	2	3	5	1	2	3	6	1	2	1	3	1
	46	38	23	28	30	19	21	31	34	30	21	53	64
YOY Profit Growth %	32.28%	138.03%	-2.98%	-57.36%	-34.65%	-49.43%	-11.05%	13.76%	13.21%	56.50%	0.24%	69.19%	89.80%
EPS in Rs	1.56	1.29	0.79	0.94	1.02	0.65	0.70	1.07	1.16	1.02	0.70	1.81	2.20
Raw filing

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	563	545	520	504	502	526	523	528	552	568	580	619	756
YOY Sales Growth %	-0.32%	0.72%	-0.59%	-14.18%	-10.80%	-3.59%	0.56%	4.73%	9.82%	7.95%	10.91%	17.37%	37.08%
	490	481	476	454	452	484	476	465	490	510	523	527	653
Material Cost %	65%	65%	68%	64%	67%	68%	68%	66%	66%	65%	66%	60%	63%
Employee Cost %	10%	9%	9%	10%	11%	11%	10%	10%	10%	11%	10%	11%	9%
Other Expenses %	13%	14%	14%	16%	12%	13%	13%	13%	12%	14%	14%	14%	14%
Operating Profit	73	64	44	50	51	42	47	63	62	57	57	93	104
OPM %	13%	12%	9%	10%	10%	8%	9%	12%	11%	10%	10%	15%	14%
	7	7	8	8	7	6	4	5	7	7	5	2	8
Exceptional items											-11
Interest	4	4	4	3	2	4	4	4	4	3	4	3	4
Depreciation	14	16	16	16	17	18	19	19	20	20	20	20	21
Profit before tax	62	51	32	38	39	26	28	45	46	41	28	71	87
	25%	26%	28%	25%	24%	26%	26%	30%	25%	26%	25%	25%	26%
Current tax	15	11	6	5	9	5	4	7	10	9	6	15	22
Deferred tax	1	2	3	5	1	2	3	6	1	2	1	3	1
	46	38	23	28	30	19	21	32	34	30	21	53	64
YOY Profit Growth %	32.44%	141.16%	-3.81%	-56.81%	-35.77%	-49.33%	-11.54%	12.17%	14.42%	56.66%	0.15%	68.18%	89.87%
EPS in Rs	1.57	1.29	0.79	0.96	1.01	0.65	0.70	1.08	1.16	1.02	0.70	1.81	2.20
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	2,184	2,217	2,133	2,079	2,319	2,524
YOY Sales Growth %		1.52%	-3.80%	-2.51%	11.54%
	1,926	1,991	1,902	1,877	2,050	2,213
Material Cost %	72%	70%	65%	67%	64%	63%
Employee Cost %	6%	8%	9%	10%	11%	10%
Other Expenses %	10%	12%	14%	13%	14%	14%
Operating Profit	258	226	231	202	269	310
OPM %	12%	10%	11%	10%	12%	12%
	32	26	30	22	21	22
Exceptional items	-14				-11	-11
Interest	8	16	16	15	15	14
Depreciation	43	46	63	72	80	82
Profit before tax	225	189	182	138	184	226
	25%	26%	26%	27%	25%	25%
Current tax	57	46	37	25	41
Deferred tax	0	3	10	12	6
	168	139	134	101	138	168
YOY Profit Growth %		-17.02%	-3.39%	-24.82%	36.18%
EPS in Rs	5.71	4.74	4.58	3.44	4.69	5.73
Dividend Payout %		17%	22%	23%	21%

Compounded Sales Growth

3 Years:: 2%
TTM:: 19%

Compounded Profit Growth

3 Years:: 0%
TTM:: 60%

Stock Price CAGR

5 Years:: 10%
3 Years:: 28%
1 Year:: 99%

Return on Equity

4 Years:: 8%
Last Year:: 8%

₹ Cr	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	1,685	1,894	1,967	2,184	2,217	2,133	2,079	2,319	2,524
YOY Sales Growth %		12.41%	3.83%	11.03%	1.52%	-3.80%	-2.51%	11.54%
	1,276	1,321	1,375	1,928	1,991	1,901	1,877	2,050	2,213
Material Cost %	62%	56%	56%	72%	70%	65%	67%	64%	63%
Employee Cost %	5%	5%	6%	6%	8%	9%	10%	11%	10%
Other Expenses %	9%	8%	8%	10%	12%	14%	13%	14%	14%
Operating Profit	410	574	592	256	227	232	202	269	310
OPM %	24%	30%	30%	12%	10%	11%	10%	12%	12%
	10	16	24	32	26	30	22	21	22
Exceptional items				-14				-11	-11
Interest	51	21	6	8	16	16	15	15	14
Depreciation	32	36	39	43	46	63	72	80	82
Profit before tax	336	533	571	223	189	183	138	184	226
	30%	32%	22%	26%	26%	26%	27%	25%	25%
Current tax	72	171	146	57	46	37	25	41
Deferred tax	27	1	-19	0	3	10	12	6
	237	361	445	166	140	135	101	138	168
YOY Profit Growth %		52.64%	23.05%	-62.74%	-15.50%	-3.26%	-25.42%	36.36%
EPS in Rs	8.42	25.40	15.24	5.64	4.77	4.61	3.44	4.69	5.73
Dividend Payout %					17%	22%	23%	21%

Compounded Sales Growth

5 Years:: 3%
3 Years:: 2%
TTM:: 19%

Compounded Profit Growth

5 Years:: -21%
3 Years:: -1%
TTM:: 60%

Stock Price CAGR

5 Years:: 10%
3 Years:: 28%
1 Year:: 99%

Return on Equity

4 Years:: 8%
Last Year:: 8%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	59	59	59	59
Reserves	1,449	1,553	1,629	1,740
	80	33	117	135
Short term borrowings	80	33	117	132
	435	600	577	653
Trade payables	314	469	428	483
Current liabilities	456	560	610	690
Total Liabilities	2,022	2,244	2,382	2,587
	835	1,037	1,183	1,273
Gross block	1,078	1,338	1,553	1,718
Accumulated depreciation	242	301	370	445
Goodwill & intangibles	9	13	14	15
CWIP	84	115	24	104
	1,103	1,093	1,175	1,210
Inventories	326	425	361	371
Trade receivables	505	471	514	603
Cash & equivalents	1	8	78	65
Current assets	920	1,120	1,151	1,228
Total Assets	2,022	2,244	2,382	2,587

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	122	290	179	214
Profit for the year	139	134	101	138
Working capital changes	-64	90	-21	-17
Direct taxes paid	-47	-42	-18	-38
	-120	-191	-154	-198
Fixed assets purchased	-212	-274	-214	-173
Fixed assets sold	2	2	1	2
Investments purchased	-18	-0		-39
Investments sold	98	68	46
	-4	-93	46	-29
Interest paid	-16	-16	-15	-15
Dividends paid	-24	-29	-23	-29
Net Cash Flow	-2	6	70	-13
Free Cash Flow	-90	16	-35	41

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	9.2%	8.6%	6.1%	7.9%
ROCE	—	12.7%	11.4%	8.3%	10.2%
Operating margin	—	8.2%	7.9%	6.3%	8.2%
Net margin	—	6.3%	6.3%	4.9%	6.0%
Debt / equity	—	0.05	0.02	0.07	0.08
Current ratio	—	2.02	2.00	1.89	1.78
Debtor days	—	84	81	91	95
Inventory days	—	75	109	93	89
Days payable	—	73	120	110	116
Cash conversion cycle	—	86	70	74	68
Working capital days	—	77	96	96	85

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 62.28%
FIIs 7.25%
DIIs 0.30%
Public 30.17%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	48.19%	48.19%	48.19%	48.19%	52.62%	52.62%	52.62%	52.62%	52.62%	57.48%	62.28%	62.28%
	2.18%	1.41%	1.39%	1.63%	1.49%	1.47%	2.59%	2.25%	2.08%	1.72%	4.87%	7.25%
Foreign portfolio investors (Cat. I)	1.94%	1.09%	1.06%	1.28%	1.31%	1.25%	1.82%	2.02%	2.02%	1.62%	3.65%	4.29%
Foreign portfolio investors (Cat. II)	0.24%	0.31%	0.33%	0.35%	0.18%	0.22%	0.77%	0.23%	0.06%	0.10%	1.22%	2.97%
	0.37%	0.30%	0.10%	0.08%	0.08%	0.07%	0.02%	0.04%	0.03%	0.02%	0.43%	0.30%
Mutual funds	0.06%	0.08%	0.09%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.29%
Alternative investment funds	0.30%	0.21%		0.05%	0.05%	0.05%		0.02%			0.41%	0.01%
	49.26%	50.10%	50.32%	50.10%	45.81%	45.83%	44.76%	45.09%	45.27%	40.78%	32.42%	30.17%
Retail (up to ₹2 lakh)	28.16%	28.20%	28.48%	27.77%	28.32%	28.21%	25.80%	25.07%	25.78%	25.93%	21.86%	21.47%
HNIs (above ₹2 lakh)	2.48%	2.78%	3.00%	3.54%	2.91%	3.22%	4.42%	4.91%	4.72%	5.11%	5.08%	4.41%
NRIs	1.96%	1.99%	2.06%	1.65%	1.69%	1.75%	1.70%	1.63%	1.64%	1.64%	1.42%	1.37%
Bodies corporate	15.37%	15.74%	15.35%	15.33%	10.95%	10.87%	11.18%	11.58%	11.26%	6.38%	2.44%	1.33%
No. of Shareholders	1,34,235	1,30,003	1,28,689	1,25,979	1,26,701	1,30,002	1,25,040	1,36,129	1,33,531	1,31,550	1,19,311	1,32,241

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding IOL Chemicals and Pharmaceuticals

No single fund or institution holds more than 1%.

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 0.29% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 17 Feb 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about IOL Chemicals and Pharmaceuticals Limited

What is the share price of IOL Chemicals and Pharmaceuticals Limited today?

IOL Chemicals and Pharmaceuticals Limited (IOLCP) last traded at ₹194.69 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of IOL Chemicals and Pharmaceuticals Limited?

About ₹5,715 crore at the latest price.

What is the P/E ratio of IOL Chemicals and Pharmaceuticals Limited?

About 34.0 times its earnings over the last 12 months.

Is IOL Chemicals and Pharmaceuticals Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy IOL Chemicals and Pharmaceuticals Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.

IOL Chemicals and Pharmaceuticals Limited share price

Price chart

Quick take

Pros

Cons

AI analysis

About IOL Chemicals and Pharmaceuticals Limited

Peer comparison

Quarterly Results

Profit & Loss

Projection — your assumptions

Related party transactions

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Balance Sheet

Cash Flows

Ratios

Shareholding Pattern

Mutual funds & institutions holding IOL Chemicals and Pharmaceuticals

Documents

Announcements

Annual reports

Credit ratings

Concalls & investor meets

Key dates

Trade with our broking desk

Latest news

In the news

From the company (NSE)

Questions about IOL Chemicals and Pharmaceuticals Limited

Have a question about this topic?

Book your free wealth consultation

Request received!

What happens next